Jump to content

Dorzolamide/timolol: Difference between revisions

From Wikipedia, the free encyclopedia
Browse history interactively
← Previous editNext edit →
Content deleted Content added
VisualWikitext
added
Line 42: Line 42:
}}
}}
<!-- Definition and medical uses -->
<!-- Definition and medical uses -->
'''Dorzolamide/timolol''' eye drops (trade name '''Cosopt''') are used to lower intraocular pressure in the eye to normal pressure and as a treatment for [[glaucoma]].<ref name=":6">{{Cite news|url=https://www.drugs.com/pro/cosopt.html|title=Cosopt - FDA prescribing information, side effects and uses|work=Drugs.com|access-date=2017-10-30|language=en-US}}</ref> This medication is a combination of two active ingredients: [[dorzolamide]] hydrochloride and [[timolol]] maleate.
'''Dorzolamide/timolol''', sold under the brand name '''Cosopt''', is a medications used to treat [[high pressure inside the eye]] including [[glaucoma]].<ref name=Daily2019/> It is a combination of [[dorzolamide]] hydrochloride and [[timolol]] maleate.<ref name=Daily2019/> It may be used when a [[beta blocker]] like timolol is not sufficient by itself.<ref name=BNF76/> It is used as an eye drop.<ref name=Daily2019/>


<!-- Side effects and mechanism -->
<!-- Side effects and mechanism -->
Both compounds work by decreasing the production of [[aqueous humor]], which works to lower intraocular pressure.
Common side effects include eye discomfort, eye redness, taste changes, and blurry vision.<ref name=Daily2019/> Serious side effects may include [[allergic reactions]] and [[heart failure]].<ref name=Daily2019/> Use is not recommended in those with [[asthma]] or a [[bradycardia|slow heart rate]].<ref name=Daily2019/> Both compounds work by decreasing the production of [[aqueous humor]], which works to lower intraocular pressure.



<!-- Society and culture -->
<!-- Society and culture -->
The combination was approved for medical use in the United States in 1998, and is supplied by [[Merck & Co.|Merck]].<ref name=":2">{{Cite web|url=https://www.newswise.com/articles/merck-receives-fda-approval-to-market-cosopt|title=Merck Receives FDA Approval to Market 'Cosopt'|website=www.newswise.com|access-date=2017-10-20}}</ref> In 2016 it was the 200th most prescribed medication in the United States with more than 2 million prescriptions.<ref>{{cite web |title=The Top 300 of 2019 |url=https://clincalc.com/DrugStats/Top300Drugs.aspx |website=clincalc.com |accessdate=22 December 2018}}</ref>
The combination was approved for medical use in the United States in 1998.<ref name=Daily2019>{{cite web |title=Dorzolamide Hydrochloride and Timolol Maleate Solution |url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=78f39126-3e3b-4633-a4e0-c1f09a794eec |website=DailyMed |accessdate=26 March 2019}}</ref> It is avaliable as a [[generic medication]].<ref name=BNF76/> A 5 milliliter bottle in the United Kingdom costs the [[NHS]] about 1.50 £ as of 2019.<ref name=BNF76>{{cite book|title=British national formulary : BNF 76|date=2018|publisher=Pharmaceutical Press|isbn=9780857113382|pages=1149|edition=76}}</ref> In the United States the wholesale cost of this amount is about 8.30 USD.<ref name=NADAC2019>{{cite web |title=NADAC as of 2019-02-27 |url=https://data.medicaid.gov/Drug-Pricing-and-Payment/NADAC-as-of-2019-02-27/s7c9-pfa6 |website=Centers for Medicare and Medicaid Services |accessdate=3 March 2019 |language=en}}</ref> In 2016 it was the 200th most prescribed medication in the United States with more than 2 million prescriptions.<ref>{{cite web |title=The Top 300 of 2019 |url=https://clincalc.com/DrugStats/Top300Drugs.aspx |website=clincalc.com |accessdate=22 December 2018}}</ref>


== Adverse effects ==
== Adverse effects ==
Line 56: Line 57:


== Pharmacology ==
== Pharmacology ==
Dorzolamide is a human [[Carboanhydrase|carboanydrase]] II inhibitor.<ref>{{Cite web|url=https://www.drugbank.ca/drugs/DB00869|title=Dorzolamide|website=www.drugbank.ca|access-date=2017-10-27}}</ref> Inhibition of carboanhydrase in the [[ciliary processes]] of the eye decreases aqueous humor secretion supposedly by decreasing the formation rate of [[bicarbonate]] ions.<ref name=":6" /> This results in reduction in both sodium and fluid transport.
Dorzolamide is a human [[Carboanhydrase|carboanydrase]] II inhibitor.<ref>{{Cite web|url=https://www.drugbank.ca/drugs/DB00869|title=Dorzolamide|website=www.drugbank.ca|access-date=2017-10-27}}</ref> Inhibition of carboanhydrase in the [[ciliary processes]] of the eye decreases aqueous humor secretion supposedly by decreasing the formation rate of [[bicarbonate]] ions.<ref name=":6">{{Cite news|url=https://www.drugs.com/pro/cosopt.html|title=Cosopt - FDA prescribing information, side effects and uses|work=Drugs.com|access-date=2017-10-30|language=en-US}}</ref> This results in reduction in both sodium and fluid transport.


Timolol is a non-selective beta-adrenergic antagonist.<ref>{{Cite web|url=https://www.drugbank.ca/drugs/DB00373|title=Timolol|website=www.drugbank.ca|access-date=2017-10-27}}</ref>
Timolol is a non-selective beta-adrenergic antagonist.<ref>{{Cite web|url=https://www.drugbank.ca/drugs/DB00373|title=Timolol|website=www.drugbank.ca|access-date=2017-10-27}}</ref>
Line 66: Line 67:


== History ==
== History ==
Cosopt gained [[Food and Drug Administration]] (FDA) approval in April 1998 and was supplied initially by [[Merck & Co.|Merck]].<ref name=":2" /> In 2016, Merck & Co. had $95.3 billion in total assets, $40.3 billion in total equity, $24.3 billion in long term debt, and $13.4 billion in working capital.<ref>{{Cite web|url=http://s21.q4cdn.com/488056881/files/doc_financials/2017/Q4/merck-q4-10k.pdf|title=Merck Form 10-K|last=|first=|date=|website=Merck|archive-url=|archive-date=|dead-url=|access-date=2017-10-27}}</ref> This same year Merck & Co spent $20 billion total split virtually evenly between research and development (R&D) and marketing efforts. &nbsp;Cosopt had annual sales of $342 million during the 12 months before June 2008.<ref name=":0">{{Cite web|url=http://www.leydig.com/publications/articles_publications-61|title=FDA Says Hi-Tech Forfeited Exclusivity; Way Paved for Approval of All Cosopt ANDAs|last=|first=|date=2008-11-07|website=Leydig|archive-url=|archive-date=|dead-url=|access-date=2017-10-27}}</ref> In September 2013, &nbsp;Merck & Co. sold the U.S. rights to their ophthalmic product line (including Cosopt) to Akorn Inc. for $52.8 million cash.<ref>{{Cite news|url=http://www.businesswire.com/news/home/20131115005439/en/Akorn-Acquires-Branded-Ophthalmic-Products-Merck|title=Akorn Acquires Three Branded Ophthalmic Products from Merck|last=|first=|date=2013-11-15|work=Business Wire|access-date=2017-10-27|archive-url=|archive-date=|dead-url=}}</ref>
Cosopt gained [[Food and Drug Administration]] (FDA) approval in April 1998 and was supplied initially by [[Merck & Co.|Merck]].<ref name=":2">{{Cite web|url=https://www.newswise.com/articles/merck-receives-fda-approval-to-market-cosopt|title=Merck Receives FDA Approval to Market 'Cosopt'|website=www.newswise.com|access-date=2017-10-20}}</ref> In 2016, Merck & Co. had $95.3 billion in total assets, $40.3 billion in total equity, $24.3 billion in long term debt, and $13.4 billion in working capital.<ref>{{Cite web|url=http://s21.q4cdn.com/488056881/files/doc_financials/2017/Q4/merck-q4-10k.pdf|title=Merck Form 10-K|last=|first=|date=|website=Merck|archive-url=|archive-date=|dead-url=|access-date=2017-10-27}}</ref> This same year Merck & Co spent $20 billion total split virtually evenly between research and development (R&D) and marketing efforts. &nbsp;Cosopt had annual sales of $342 million during the 12 months before June 2008.<ref name=":0">{{Cite web|url=http://www.leydig.com/publications/articles_publications-61|title=FDA Says Hi-Tech Forfeited Exclusivity; Way Paved for Approval of All Cosopt ANDAs|last=|first=|date=2008-11-07|website=Leydig|archive-url=|archive-date=|dead-url=|access-date=2017-10-27}}</ref> In September 2013, &nbsp;Merck & Co. sold the U.S. rights to their ophthalmic product line (including Cosopt) to Akorn Inc. for $52.8 million cash.<ref>{{Cite news|url=http://www.businesswire.com/news/home/20131115005439/en/Akorn-Acquires-Branded-Ophthalmic-Products-Merck|title=Akorn Acquires Three Branded Ophthalmic Products from Merck|last=|first=|date=2013-11-15|work=Business Wire|access-date=2017-10-27|archive-url=|archive-date=|dead-url=}}</ref>


Upon the original patent expiration, Hi-Tech Pharma was the first of many generic competitors to submit an abbreviated new drug application (ANDA) for dorzolamide hydrochloride/timolol maleate eye drops.<ref name=":1">{{Cite news|url=https://www.law360.com/articles/68255/hi-tech-sues-fda-to-get-generic-cosopt-exclusivity|title=Hi-Tech Sues FDA To Get Generic Cosopt Exclusivity|last=|first=|date=2008-08-04|work=Law360|access-date=2017-10-27|archive-url=|archive-date=|dead-url=}}</ref> Hi-Tech Pharma’s ANDA was approved on October 28, 2008. &nbsp;At the time, controversy surrounded the approval of this first ANDA. &nbsp;Hi-Tech sued the FDA for their right to 180 market exclusivity as laid out in the Hatch-Waxman Act. Apotex, another firm seeking an ANDA approval for generic Cosopt, argued that Hi-Tech “forfeited its rights to market exclusivity because it has failed to market the drug within 30 months of its ANDA submission or within 75 days after Merck withdrew its patent information.”<ref name=":1" /> The FDA upheld their previous exclusivity decisions on acarbose and granisetron, allowing both Hi-Tech and Apotex to make a generic version of Cosopt.<ref name=":0" /> Soon after, ANDAs from Sandoz, Bausch & Laumb, TEVA and others were also approved.<ref name=":4">{{Cite web|url=https://www.drugs.com/availability/generic-cosopt.html|title=Generic Cosopt Availability|last=|first=|date=|website=Drugs.com|archive-url=|archive-date=|dead-url=|access-date=2017-10-27}}</ref>
Upon the original patent expiration, Hi-Tech Pharma was the first of many generic competitors to submit an abbreviated new drug application (ANDA) for dorzolamide hydrochloride/timolol maleate eye drops.<ref name=":1">{{Cite news|url=https://www.law360.com/articles/68255/hi-tech-sues-fda-to-get-generic-cosopt-exclusivity|title=Hi-Tech Sues FDA To Get Generic Cosopt Exclusivity|last=|first=|date=2008-08-04|work=Law360|access-date=2017-10-27|archive-url=|archive-date=|dead-url=}}</ref> Hi-Tech Pharma’s ANDA was approved on October 28, 2008. &nbsp;At the time, controversy surrounded the approval of this first ANDA. &nbsp;Hi-Tech sued the FDA for their right to 180 market exclusivity as laid out in the Hatch-Waxman Act. Apotex, another firm seeking an ANDA approval for generic Cosopt, argued that Hi-Tech “forfeited its rights to market exclusivity because it has failed to market the drug within 30 months of its ANDA submission or within 75 days after Merck withdrew its patent information.”<ref name=":1" /> The FDA upheld their previous exclusivity decisions on acarbose and granisetron, allowing both Hi-Tech and Apotex to make a generic version of Cosopt.<ref name=":0" /> Soon after, ANDAs from Sandoz, Bausch & Laumb, TEVA and others were also approved.<ref name=":4">{{Cite web|url=https://www.drugs.com/availability/generic-cosopt.html|title=Generic Cosopt Availability|last=|first=|date=|website=Drugs.com|archive-url=|archive-date=|dead-url=|access-date=2017-10-27}}</ref>

Revision as of 13:50, 26 March 2019

Dorzolamide hydrochloride/Timolol maleate eye drops
Combination of
Dorzolamide hydrochlorideCarboanhydrase inhibitor
Timolol maleateBeta blocker
Clinical data
Trade namesCosopt
Routes of
administration		Ophthalmic
ATC code
Legal status
Legal status
Identifiers
PubChem CID
CompTox Dashboard (EPA)
  (verify)

Dorzolamide/timolol, sold under the brand name Cosopt, is a medications used to treat high pressure inside the eye including glaucoma.[1] It is a combination of dorzolamide hydrochloride and timolol maleate.[1] It may be used when a beta blocker like timolol is not sufficient by itself.[2] It is used as an eye drop.[1]

Common side effects include eye discomfort, eye redness, taste changes, and blurry vision.[1] Serious side effects may include allergic reactions and heart failure.[1] Use is not recommended in those with asthma or a slow heart rate.[1] Both compounds work by decreasing the production of aqueous humor, which works to lower intraocular pressure.


The combination was approved for medical use in the United States in 1998.[1] It is avaliable as a generic medication.[2] A 5 milliliter bottle in the United Kingdom costs the NHS about 1.50 £ as of 2019.[2] In the United States the wholesale cost of this amount is about 8.30 USD.[3] In 2016 it was the 200th most prescribed medication in the United States with more than 2 million prescriptions.[4]

Adverse effects

Common adverse effects include temporarily blurred vision, cloudy vision, double vision, temporary burning/stinging/itching of the eye, watery eyes, feeling as if something is in the eye, drooping eyelid, sensitivity to light, cough, flu symptoms, nausea, and stomach pain.[5]

More serious adverse effects include dizziness, slow or irregular heartbeat, muscle weakness, mental/mood changes, and coldness/numbness/pain in the hands or feet.[5]

Pharmacology

Dorzolamide is a human carboanydrase II inhibitor.[6] Inhibition of carboanhydrase in the ciliary processes of the eye decreases aqueous humor secretion supposedly by decreasing the formation rate of bicarbonate ions.[7] This results in reduction in both sodium and fluid transport.

Timolol is a non-selective beta-adrenergic antagonist.[8]

Comparison to other products

Despite each of the active ingredients being availed in their own respective formulations, combination formulations are typically more convenient for the patient without sacrificing any quality in therapy. In the case of Cosopt, the combination formulation dosed twice daily provides equivalent treatment to both dorzolamide 2% dosed two times daily and timolol 0.5% dosed three times daily.[9] Specifically, the mean reduction in intraocular pressure was 27.4% for the combination product, 15.5% for dorzolamide 2%, and 22.2% for timolol 0.5%.

Compared to other products such as latanoprost, both are equally efficacious with regard to lowering intraocular pressure and getting patients to reach their target intraocular pressure.[9] Cosopt, though, is typically less well tolerated than other treatments due to a well documented feeling of ocular burning upon administration.

History

Cosopt gained Food and Drug Administration (FDA) approval in April 1998 and was supplied initially by Merck.[10] In 2016, Merck & Co. had $95.3 billion in total assets, $40.3 billion in total equity, $24.3 billion in long term debt, and $13.4 billion in working capital.[11] This same year Merck & Co spent $20 billion total split virtually evenly between research and development (R&D) and marketing efforts.  Cosopt had annual sales of $342 million during the 12 months before June 2008.[12] In September 2013,  Merck & Co. sold the U.S. rights to their ophthalmic product line (including Cosopt) to Akorn Inc. for $52.8 million cash.[13]

Upon the original patent expiration, Hi-Tech Pharma was the first of many generic competitors to submit an abbreviated new drug application (ANDA) for dorzolamide hydrochloride/timolol maleate eye drops.[14] Hi-Tech Pharma’s ANDA was approved on October 28, 2008.  At the time, controversy surrounded the approval of this first ANDA.  Hi-Tech sued the FDA for their right to 180 market exclusivity as laid out in the Hatch-Waxman Act. Apotex, another firm seeking an ANDA approval for generic Cosopt, argued that Hi-Tech “forfeited its rights to market exclusivity because it has failed to market the drug within 30 months of its ANDA submission or within 75 days after Merck withdrew its patent information.”[14] The FDA upheld their previous exclusivity decisions on acarbose and granisetron, allowing both Hi-Tech and Apotex to make a generic version of Cosopt.[12] Soon after, ANDAs from Sandoz, Bausch & Laumb, TEVA and others were also approved.[15]

Just over a year before Merck sold their ophthalmic line to Akorn, Akorn developed a new formulation of dorzolamide hydrochloride/timolol maleate called Cosopt PF, which is simply a preservative free formulation of Cosopt.[16] It gained FDA approval in July 2012 and is currently protected by market exclusivity.

Society and culture

Legality

In the United States, Cosopt, as well as its generics, is only available to patients with a valid prescription.[15]

Cost

The brand name Cosopt currently costs upwards of $200 after discounts[17] while the generic formulation costs around $70 cash.[18] The more recent preservative free formulation can be purchased for less than the original brand name formulation at around $160[19]

References

  1. ^ a b c d e f g "Dorzolamide Hydrochloride and Timolol Maleate Solution". DailyMed. Retrieved 26 March 2019.
  2. ^ a b c British national formulary : BNF 76 (76 ed.). Pharmaceutical Press. 2018. p. 1149. ISBN 9780857113382.
  3. ^ "NADAC as of 2019-02-27". Centers for Medicare and Medicaid Services. Retrieved 3 March 2019.
  4. ^ "The Top 300 of 2019". clincalc.com. Retrieved 22 December 2018.
  5. ^ a b "Common Side Effects of Cosopt (Dorzolamide Hydrochloride-Timolol Maleate Ophthalmic Solution) Drug Center - RxList". RxList. Retrieved 2017-10-30.
  6. ^ "Dorzolamide". www.drugbank.ca. Retrieved 2017-10-27.
  7. ^ "Cosopt - FDA prescribing information, side effects and uses". Drugs.com. Retrieved 2017-10-30.
  8. ^ "Timolol". www.drugbank.ca. Retrieved 2017-10-27.
  9. ^ a b Bartlett, Jimmy (2008). Clinical Ocular Pharmacology. https://books.google.com/books?id=Eybg7fbs65MC&pg=PA166&lpg=PA166&dq=cosopt+pharmacology&source=bl&ots=gFP7IEk7yz&sig=QznLSog1YWagh_FKcB3D5TkcWnA&hl=en&sa=X&ved=0ahUKEwjM2qPr3ZbXAhVCLyYKHa0UBrEQ6AEIVzAJ#v=onepage&q=cosopt%20pharmacology&f=false. p. 166. {{cite book}}: External link in |location= (help)CS1 maint: location (link) CS1 maint: location missing publisher (link)
  10. ^ "Merck Receives FDA Approval to Market 'Cosopt'". www.newswise.com. Retrieved 2017-10-20.
  11. ^ "Merck Form 10-K" (PDF). Merck. Retrieved 2017-10-27. {{cite web}}: Cite has empty unknown parameter: |dead-url= (help)
  12. ^ a b "FDA Says Hi-Tech Forfeited Exclusivity; Way Paved for Approval of All Cosopt ANDAs". Leydig. 2008-11-07. Retrieved 2017-10-27. {{cite web}}: Cite has empty unknown parameter: |dead-url= (help)
  13. ^ "Akorn Acquires Three Branded Ophthalmic Products from Merck". Business Wire. 2013-11-15. Retrieved 2017-10-27. {{cite news}}: Cite has empty unknown parameter: |dead-url= (help)
  14. ^ a b "Hi-Tech Sues FDA To Get Generic Cosopt Exclusivity". Law360. 2008-08-04. Retrieved 2017-10-27. {{cite news}}: Cite has empty unknown parameter: |dead-url= (help)
  15. ^ a b "Generic Cosopt Availability". Drugs.com. Retrieved 2017-10-27. {{cite web}}: Cite has empty unknown parameter: |dead-url= (help)
  16. ^ "October 2017 - When do the COSOPT PF patents expire, and when will generic COSOPT PF be available?". Deep knowledge on small-molecule drugs and the 120,000 global patents covering them. Retrieved 2017-10-29.
  17. ^ "Prices and Coupons for Cosopt". Retrieved 2017-10-29.
  18. ^ "Prices and Coupons for Cosopt". www.goodrx.com. Retrieved 2017-10-29.
  19. ^ "Prices and Coupons for Cosopt PF". www.goodrx.com. Retrieved 2017-10-29.
Retrieved from "https://en.wikipedia.org/enwiki/w/index.php?title=Dorzolamide/timolol&oldid=889561430"